drugset / Trial / NCT00004870
Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Phase 1/2
Completed
The University of Texas Health Science Center at San Antonio
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Gene therapy such as oblimersen may make tumor cells more sensitive to chemotherapy drugs. Combining irinotecan and oblimersen may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining oblimersen and irinotecan in treating patients who have metastatic or recurrent colorectal cancer.
Timeline
- Start
- 2000-06
- Primary completion
- 2002-09
- Completion
- 2002-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | — | Intravenous |
| Subject | oblimersen sodium | Antisense oligonucleotide | — | Intravenous |